New drug combo tested for tough-to-treat cancers that resist current treatments
Disease control
Ongoing
This study is testing whether adding an experimental drug called Q702 to an existing immunotherapy (pembrolizumab) can help control advanced cancers that have stopped responding to previous treatments. The trial will enroll 120 people with advanced esophageal, stomach, liver, or …
Phase: PHASE1, PHASE2 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC